- Research article
- Open Access
- Open Peer Review
Renal cell carcinoma primary cultures maintain genomic and phenotypic profile of parental tumor tissues
- Ingrid Cifola†1,
- Cristina Bianchi†2,
- Eleonora Mangano1,
- Silvia Bombelli2,
- Fabio Frascati1,
- Ester Fasoli3,
- Stefano Ferrero3,
- Vitalba Di Stefano2,
- Maria A Zipeto2,
- Fulvio Magni2,
- Stefano Signorini4,
- Cristina Battaglia5Email author and
- Roberto A Perego2Email author
© Cifola et al; licensee BioMed Central Ltd. 2011
- Received: 27 October 2010
- Accepted: 13 June 2011
- Published: 13 June 2011
Clear cell renal cell carcinoma (ccRCC) is characterized by recurrent copy number alterations (CNAs) and loss of heterozygosity (LOH), which may have potential diagnostic and prognostic applications. Here, we explored whether ccRCC primary cultures, established from surgical tumor specimens, maintain the DNA profile of parental tumor tissues allowing a more confident CNAs and LOH discrimination with respect to the original tissues.
We established a collection of 9 phenotypically well-characterized ccRCC primary cell cultures. Using the Affymetrix SNP array technology, we performed the genome-wide copy number (CN) profiling of both cultures and corresponding tumor tissues. Global concordance for each culture/tissue pair was assayed evaluating the correlations between whole-genome CN profiles and SNP allelic calls. CN analysis was performed using the two CNAG v3.0 and Partek software, and comparing results returned by two different algorithms (Hidden Markov Model and Genomic Segmentation).
A very good overlap between the CNAs of each culture and corresponding tissue was observed. The finding, reinforced by high whole-genome CN correlations and SNP call concordances, provided evidence that each culture was derived from its corresponding tissue and maintained the genomic alterations of parental tumor. In addition, primary culture DNA profile remained stable for at least 3 weeks, till to third passage. These cultures showed a greater cell homogeneity and enrichment in tumor component than original tissues, thus enabling a better discrimination of CNAs and LOH. Especially for hemizygous deletions, primary cultures presented more evident CN losses, typically accompanied by LOH; differently, in original tissues the intensity of these deletions was weaken by normal cell contamination and LOH calls were missed.
ccRCC primary cultures are a reliable in vitro model, well-reproducing original tumor genetics and phenotype, potentially useful for future functional approaches aimed to study genes or pathways involved in ccRCC etiopathogenesis and to identify novel clinical markers or therapeutic targets. Moreover, SNP array technology proved to be a powerful tool to better define the cell composition and homogeneity of RCC primary cultures.
- Single Nucleotide Polymorphism Array
- Copy Number Loss
- Parental Tissue
- Single Nucleotide Polymorphism Call
- Normal Cell Contamination
The clear cell subtype of renal cell carcinoma (ccRCC) accounts for 85% of all RCCs and occurs as familial or, more often, sporadic forms. It is characterized by recurrent genetic anomalies, like copy number alterations (CNAs) and loss of heterozygosity (LOH), that involve specific chromosomes (chrs) and result in deletions with LOH on chrs 3p (often involving the von Hippel Lindau (VHL) locus in 3p26-p25), 6q, 8p, 9p and 14q, and duplications of chrs 5q and 7 [1–3]. Evidences suggest that this peculiar pattern of genomic instability represents a tumor-specific molecular fingerprint useful for diagnostic and prognostic applications [3–5]. However, more work still needs to completely clarify the complex molecular pathogenesis of ccRCC. Although the involvement of the VHL tumor suppressor gene has been demonstrated in all familial and in 80-90% sporadic ccRCCs, the remaining 10-20% harbors wild-type VHL [6, 7], suggesting that, despite their identical histological phenotype, these tumors have an intrinsic molecular heterogeneity that still needs to be unraveled [6, 8]. The recognition of this molecular heterogeneity might improve the selection of patients for targeted therapies and allow the identification of specific oncogenes and tumor suppressor genes to be used as novel clinical markers or therapeutic targets.
The current availability of high-throughput platforms to assess molecular changes at genome-wide level might provide an opportunity to achieve this goal. Presently a comprehensive and detailed genomic profiling of DNA alterations is possible by using the single nucleotide polymorphism (SNP) array technology. Unlike CGH technique, the SNP array platform allows the simultaneous analysis of both chromosomal and allelic imbalances  and the distinction between LOH associated with CN changes (such as hemizygous deletions) and CN neutral status (often termed as uniparental disomy) . In addition, this technology is able to provide information about the fraction of normal and tumor cells present in the tumor tissue samples . This allows a more complete definition of the complex genetic rearrangements associated with cancer pathologies. Moreover, since the regions of LOH accompanied by deletion (representing the second hit of Knudson's hypothesis) are of particular interest because they may contain genes involved in tumor etiology, the assessment of deletion/LOH areas represents a useful approach to identify regions potentially harboring novel tumor suppressor genes . Accordingly, in a previous study, we used the SNP array technology to characterize the whole-genome DNA profile of a collection of ccRCC tissue samples to find novel chromosomal regions and genes potentially interesting as candidate tumor markers .
However, in ccRCC specimens, as in most solid tumor tissues, the molecular analyses may be affected by tissue heterogeneity due to the presence of necrotic areas and non-tumor cells, such as tumor-infiltrating leukocytes, endothelial cells and fibroblasts . With the purpose to increase the quality of data by minimizing this "background noise", several different technical approaches have been explored . Tissue heterogeneity must be considered also when evaluating which are the most appropriate computational tools to process and analyze array-based CN data [11, 16].
Thus, to overcome the problem of tissue heterogeneity and to prospectively perform in vitro functional studies aimed to better understand ccRCC molecular pathogenesis, it is necessary to have a viable and more homogeneous cell material retaining the phenotypic and genomic profile of original tissue. A possible strategy to face these requirements is to adapt fresh ccRCC tissue specimens to grow in vitro as primary cell cultures, which provide a good quality, homogeneous and well-characterized cellular material, enriched with tumor cell component  and retaining at the first passages the phenotypic and proteomic profile of the corresponding tissues from which they derive [15, 18, 19]. Hence, primary cultures represent a better in vitro tumor model than stable cell lines, that can be even very different from the original tissues and thus not at all representative . Anyway, the reliability of data obtained from primary cultures strictly depends on their careful cytological characterization, especially regarding possible cell contaminations that might influence data interpretation with misleading effects.
In this study, we investigated whether ccRCC primary cultures, established from surgical tumor specimens and phenotypically well-characterized, maintain the DNA profile of parental tumor tissues and allow a better discrimination of CNAs and LOH with respect to original tissues. Till now, the comparison of DNA profile between tumor primary cultures and parental tissues has been reported, with discordant results, in melanoma , neuroblastoma  and glioblastoma , using either SNP array or array-CGH techniques, and in RCC  only using traditional CGH on metaphase spreads and short-term primary cultures not extensively characterized.
ccRCC primary culture preparation and immunophenotypic characterization
Clinical data of the nine clear cell RCC cases from which primary cultures have been prepared.
Tumor size (cm)
Tumor stage (pT)/Grade
For immunofluorescence microscopy, ccRCC cells grown on glass cover slips were fixed for 30 min in 4% paraformaldehyde PBS buffer, pH 7.2, at 37°C, rinsed with PBS, pre-incubated for 15 min in GDB buffer (0.02 mol/l sodium phosphate buffer, pH 7.4, with 0.45 mol/l NaCl and 0.5% BSA) containing 0.3% Triton X-100, and incubated with mouse monoclonal antibodies (mAbs) against pan-cytokeratin (clone MNF-116, Dako, Glostrup, Denmark; dilution 1:200), vimentin (clone V9, Dako; dilution 1:200), carbonic anhydrase IX (CA9) (clone M75, dilution 1:50; a gift from Prof. Pastorekova, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovak Republic) and FITC-conjugated mAb against CD13 (clone CBL 169F, Chemicon, Billerica, MA, USA; dilution 1:25) for 2 hrs at room temperature. After washing in PBS, cover slips were incubated for 1 hr with goat anti-mouse Alexa-Fluor488-conjugated IgG secondary antibody (Molecular Probes, Invitrogen Life Technologies, Carlsbad, CA, USA; dilution 1:100). Nuclear counterstaining was performed by incubation for 5 min with 1 μM DAPI (Sigma-Aldrich) in PBS buffer. Immunofluorescence micrographs were obtained using a Zeiss Axiovert 200 inverted microscope (Zeiss Inc., Oberkochen, Germany), at 400× magnification, equipped with a CoolSNAP HQ camera driven by Metamorph software. For flow cytometry analysis, cells at the first confluence (p1) were detached from plates with 0.25% trypsin-EDTA (Sigma-Aldrich), rinsed and incubated for 15 min in PBS with 5% FCS. For CD13 and CA9 staining, cells were incubated for 15 min at room temperature with the specific mouse mAbs. Cytokeratin and vimentin staining was performed using the specific mouse mAbs after permeabilization with IntraStain solution (Dako). Cells were then incubated with goat anti-mouse Alexa-Fluor488-conjugated IgG secondary antibody (Molecular Probes, Invitrogen Life Technologies) for 30 min at 4°C and counted by the FACSCalibur flow cytometer and CellQuest software (BD Biosciences) until 30,000 events were acquired.
Western Blot analysis
For each case, cells plated in a 6 mm-Petri dish were lysated when at the first confluence (p1), and the extracted proteins quantified by the Bio-Rad microassay (BioRad, Hercules, CA, USA), as previously described . 30 μg proteins were separated on NuPage 4-12% Bis-Tris pre-cast gels (Invitrogen Life Technologies) and blotted onto nitrocellulose membranes probed in 10 mM Tris-HCl, pH 8, and 3% BSA, with mouse mAb against CA9 (clone M75, dilution 1:50). Detection was performed using a secondary antibody coupled with horseradish peroxidase for 1 hr at room temperature and the SuperSignal West Pico detection system (Pierce, Rockford, IL, USA).
DNA extraction and target preparation for Affymetrix SNP Arrays
The genomic studies were performed on all ccRCC primary cultures at first confluence (p1); in addition, for 80MLa and 81BPG cases also cultures at second confluence (p2) or at second (p2) and third (p3) confluences were characterized. Genomic DNA was extracted from primary cell cultures by QIAmp DNA Mini kit (Qiagen, Hilden, Germany), according to manufacturer's cultured cell protocol. DNA from tumor tissues and autologous whole blood samples, used as normal control, was extracted using a standard proteinase K cell lysis and phenol-chloroform procedure. Samples were quantified by ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and checked by electrophoresis on 0.8% agarose gel. Starting from 250 ng, DNA samples were processed using the GeneChip® Human Mapping 50K Hind Assay kit (Affymetrix, Santa Clara, CA, USA), according to manufacturer's protocol, and hybridized onto GeneChip® Human Mapping 50K Hind Arrays. Intensity signals were acquired by Affymetrix GeneChip® Scanner 3000 7G and quantified by GTYPE v4.1 software (Affymetrix), using the BRLMM algorithm to assign SNP calls and to generate CHP files. A SNP call rate greater than 95% was considered as "good quality" threshold.
Genome-wide copy number and LOH profiling in ccRCC primary cultures and tumor tissues
To assess copy number alterations (CNAs) and loss of heterozygosity (LOH), two different software CNAG (version 3.0) and Partek Genomics Suite (version 6.5) were applied. CNAG is a well known software commonly used to analyze SNP array derived-CN data in tumor samples . The AsCNAR (allele-specific copy-number analysis using anonymous reference) algorithm was applied to perform a "self-reference paired analysis", by comparing each culture and corresponding tumor tissue to the matched blood sample. All resulting profiles (global log ratio CN profiles; allele log ratio CN profiles; Hidden Markov Model (HMM)-inferred CN state; HMM-inferred LOH) were visually inspected to identify regions affected by aberrations. To increase data reliability, we chose to include only CNAs longer than 2 Mb (resolution limit of 50K SNP array platform). CNAG software was also used to obtain a genome-wide map of LOH events occurring in each culture or tumor tissue with respect to matched blood. Only the LOH events defined as statistically significant by CNAG (with LOH likelihood higher than 30, as default threshold, and thus visualized in the HMM-LOH track) and covering regions longer than 2 Mb were considered.
The same paired analysis was performed using Partek Genomics Suite software (Partek Inc., St Louis, MO, USA), starting from CEL intensity files and applying the two alternative algorithms Hidden Markov Model (HMM, the same used by CNAG) and Genomic Segmentation (GS). For HMM analysis, default parameters were adopted; for GS analysis, the default window of 10 contiguous SNPs was maintained, Signal to noise ratio at 0.5 and p-value at 0.001 were also adopted.
To estimate the global concordance between the genomic profile of each primary culture and its parental tissue, a paired whole-genome CN correlation was calculated, starting from the CNAG "HMM-CN state" data (SNP copy number status inferred by HMM), and applying Spearman's regression method. SNP call concordance index and Spearman's correlation between the CNAG SNP allelic calls of two matched samples were also calculated. For SNP call concordance, a contingency table of the counts for each combination of the four genotype categories (AA, AB, BB, NoCall) for culture (in row) and matched tissue (in column) was accomplished. The concordance index was calculated as a ratio between the sum of principal diagonal counts and 56,859 (total number of real informative SNPs on 50K Hind arrays), multiplied by 100. A SNP call concordance higher than 60% for two related samples was adopted as threshold. All statistical analysis were performed in R environment.
Phenotypic characterization of ccRCC primary cultures
Genome-wide assessment of CNAs and LOH in ccRCC primary cultures
The Affymetrix 50K SNP Array platform was used to perform the whole-genome SNP profiling of 12 samples from ccRCC primary cultures, nine at the first confluence (p1), two at the second confluence (p2), and one at the third confluence (p3). In addition, 9 samples from the corresponding original tumor tissues and 9 autologous blood samples were analyzed. We obtained an average SNP call rate equal to 98.54%, ranging from 95.79% to 99.67%, and all arrays were included in the analyses. Using CNAG v3.0 software, we performed the genome-wide profiling of CNAs in each tumor primary culture at p1. Globally, the typical "clear cell RCC" genomic signature was confirmed, including deletions on chr 3p and amplifications on chrs 5q and 7 (see Additional File 1), the same signature that we previously described in another set of ccRCC tissue samples .
Genome-wide comparison of DNA profile of primary cultures and original tumor tissues
Estimations of the global correlation between the genomic profile of each primary culture and corresponding parental tissue.
Spearman's correlation on HMM-CN state
SNP call concordance index
Spearman's correlation on SNP calls
Concerning LOH profile, 60CC culture exactly maintained all the allelic imbalances, with corresponding CN status, found in the original tumor tissue, while 50PC, 61FG and 73PG cultures confirmed the absence of LOH observed in parental tissues (Figure 2). The remaining five primary cultures presented a total of 11 LOH regions that were not detected by CNAG in original tissues because not reaching the LOH likelihood threshold to be classified as statistically significant by the software and thus visualized in the HMM-LOH track. Viceversa, we did not found LOH events occurring in tumor tissues and not confirmed in corresponding cultures.
Lastly, we performed the same paired analysis between tumor primary culture and parental tissue using Partek Genomics Suite software, which allows to choose between two alternative CN algorithms. Globally, using the HMM-based algorithm (the same used by CNAG), Partek returned results overlapping with CNAG analysis. Differently, when applying the GS algorithm, Partek was able to retrieve all those CN losses missed to be classified as statistically significant in tissue samples by the CNAG HMM algorithm. This is illustrated for 66SML case in Additional File 4. These results confirmed that in tissue samples these deletions were really present even if less visible than in cultures due to sample heterogeneity, and they did not arise de novo in primary cultures.
In this study, we investigated whether the in vitro model of ccRCC primary cell cultures, established from surgical tumor specimens, well reproduces the DNA profile of parental tumor tissues, thus allowing a more confident CNAs and LOH discrimination with respect to the original tissues. Tumor cells from ccRCC surgical specimens may be adapted to in vitro growth with high efficiency, independently from any clinico-pathological characteristic of patients, as we previously confirmed also in a wide series of well-characterized samples [18, 19]. The growth and survival rate of our ccRCC cultures were in agreement with those reported by other authors  and proved that our primary cultures grow for the first four passages without difficulties . The cellular composition of our cultures was very homogeneous: more than 90% of cultured cells were of proximal tubular origin, with morphological characteristics typical of ccRCC, and more than 60% of cells were positive for CA9, a biomarker present in almost all ccRCC cases and expressed in most, although not all, of the malignant clear cells of each single positive case [26, 28]. When evaluated by Western Blot, CA9 expression was quite strong in all samples, except for 73PG culture where it was undetectable. Notably, about this latter culture, we found an identical normal genomic profile in primary culture and parental tissue in terms of both CNAs and LOH (with the resolution power of the 50K SNP array platform), although the tumor tissue sample, unlike primary culture, showed a CA9 expression by immunohistochemistry (data not shown). This finding is in agreement with another paper reporting a ccRCC case which expressed CA9 in the surgical tissue sample but not in the corresponding primary culture . Moreover, in our experience with a wide series of samples , we observed other few ccRCC cases showing a CA9 positivity at tissue level but not in corresponding primary cultures. Excluding tissue sampling mistakes, this behavior might be due to a transitory expression of CA9 during tissue excision. In fact, it is known that surgical conditions, like tissue ischemia after renal artery clamping and subsequent hypoxia, may up-regulate the expression of downstream targets of HIF-1 (hypoxia inducible factor 1), including CA9, that conversely should not be induced under normoxic conditions like those applied for primary cultures . On the other hand, the outgrowth of normal tubular epithelial cells in 73PG culture is unlikely based on the extensive phenotypic characterization we performed on all our cultures .
Up to now, karyotypic characterization of RCC primary cultures has been performed only by classical cytogenetic G-banding  or CGH technique . In our knowledge, this is the first study applying the Affymetrix SNP array technology to assess at genome-wide level both CNAs and LOH in ccRCC primary cultures. Globally, our cultures confirmed the typical ccRCC genomic signature [13, 23, 30]. These cultures typically showed alterations on at most 4 or 5 chromosomes. Only two samples made exception: 73PG culture did not show alterations in both CN and LOH profiles, while 60CC showed CNAs on all chromosomes. In particular, 60CC primary culture, as well as its corresponding tissue, showed an atypical ccRCC genomic profile more similar to that of chromophobe subtype (characterized by wide losses on chrs 1, 2, 6, 10, 13, 17 and 21), notwithstanding its typical "clear cell" histology.
It should also be noted that while 73PG specimen derived from a small in size tumor, suggestive of an early stage of neoplastic progression, 60CC specimen derived from the largest one, probably associated with a more advance stage of tumor progression characterized by an aberrant and "clear cell" atypical genomic profile .
Up today, very few genomic comparisons between short-term primary cultures and parental tumor tissues have been performed. In glioblastoma, for example, the genomic profile of primary cultures, assessed by array-CGH, resulted considerably different from that of parental tumors, with changes progressively occurring already after 2 weeks of culture, resulting in an inconsistent representation of tumor biology . In melanoma  and neuroblastoma , instead, using SNP array technology, primary cultures showed to encompass the spectrum of significant alterations present in primary tumors, thus providing a genetically appropriate in vitro model for functional genomics characterizations.
Concerning RCC, up till now the comparisons between primary cultures and tumor tissues mainly regarded phenotypic characterizations and proteomic profiling [15, 18, 31]. A comparison of the genomic profile between primary cultures and parental tissues has been reported only by Sanjmyatav et al. by using traditional CGH . Their DNA profiling showed a poor overlap of CNAs between ccRCC primary cultures and parental tumor tissues. In fact, only 3 out of 8 ccRCC cultures exactly showed the same DNA alterations present in the corresponding tissues. In addition, other 3 cultures did not show any of the CNAs found in the corresponding tissue samples and resulted diploid. Probably, the poor overlap of CNAs obtained by Sanjmyatav et al.  was due both to the low sensitivity and resolution level of the technique used (i.e. CGH on metaphase chromosome spreads) and to the not extensive cytological characterization of primary cultures. These findings highlight the importance of a careful phenotypic characterization of primary cultures for a correct interpretation of genomic results.
Globally, these few genomic comparison studies between primary cultures and parental tissues point out that the use of tumor primary cultures as in vitro model for genetic analysis or functional studies must be distinctively evaluated tumor by tumor and that in any case it depends on the level of phenotypic characterization of primary cultures.
Looking at the genome-wide CN profiles, our results indicated that 7 out of 9 well-characterized primary cultures exactly reproduced the DNA profile of the corresponding tumor tissues. The other two cultures (59RG and 66SML) maintained all but one the CNAs showed by the original tissues. These findings are in agreement with Lin et al. who evidenced that in melanoma some significant alterations present in original tissues (as a deletion on chr 13q) were almost undetectable in cultured cells, despite the landscape of genomic alterations was strikingly similar . However, it must be pointed out that even if primary cultures might have lost some genomic alterations present in original tumor tissues, they probably correspond to some "passenger mutations", that do not confer selective growth advantage to tumor cells and thus might be lost in cultured cells, and not to "driver mutations" .
Although the good overlap of CN profiles between each our primary culture and corresponding tissue, we obtained a CN correlation mean value equal to 0.73 (by Spearman regression method), a value just a little higher than that reported for glioblastoma cultures and tissues (Pearson mean 0.62) . The reason is in the wide range of variance we obtained among our 9 cases (range 0.30-0.99), mainly due to the contribution of one case (66SML) on the mean. Although this variability seems too high for conclusive messages, it must be noted that in our series it essentially depends on a software issue. In fact, we used the CNAG "HMM-CN state" data, that is the SNP copy number status inferred by HMM algorithm and visualized in the HMM-CN state track. However, in the presence of a high sample heterogeneity, as in the case of 66SML tissue (illustrated in Figure 4), the HMM-CN state data missed to detect CN aberrations, even if present, because their CN values did not reach the software threshold for a statistical significance. For this reason, the 66SML sample had the lowest CN correlation coefficient between culture and tissue (Spearman 0.30), a value that does not really reflect a poor overlap but only a software constraint.
Similarly to those found in neuroblastoma , the SNP call concordance indexes and the Spearman's correlation coefficients calculated on CNAG SNP allelic calls indicated a strong correlation at SNP genotype level between our cultures and parental tissues, 66SML sample included, thus confirming that each primary culture really derived from its corresponding tissue.
Notably, in six samples, CNAs were more evident and better discriminated in primary cultures than in corresponding tumor tissues. This phenomenon principally occurred in deleted regions and it is due to the different cellular composition of the two samples and it was also observed in neuroblastoma tissues and derived cell lines . Tumor tissues are heterogeneous and comprise a mixture of tumor and normal cells (endothelial cells, leukocytes, fibroblasts). For this reason, the copy number values corresponding to DNA alterations of tumor cells are inevitably "diluted" by the diploid values coming from normal cells. Differently, primary cultures were more homogeneous in terms of tumor component, as shown by their phenotypic characterization, and thus presented better defined CNAs. Tumor tissue heterogeneity reflects also on LOH detection. In fact, the software used in the analysis not only detected the allele retained by the tumor, but also the second allele still present in normal cells; in these cases the LOH call will be missed . In our ccRCC primary cultures, instead, hemizygous deletions were accompanied by LOH calls, confirming the great sample homogeneity that enables to discriminate CNAs and LOH. Thus, the presence of LOH calls in deleted regions could be adopted as a parameter to evaluate the degree of tumor sample purity and the level of normal cell contamination and consequently the origin of cultured cells, highlighting the power of SNP array technology with respect to CGH technique. Such an evidence appears more important taking into account that since today there is not a single universally applied method able to certainly make these evaluations .
The high cell homogeneity observed in our ccRCC cultures might explain also the additional CNAs found in 4 of them but not in original tissues. The acquisition of these alterations de novo during in vitro growth is unlikely since cultures were analyzed at first confluence. Moreover, the genomic analysis of some cultures at second and third confluences provided evidence that these cultures did not accumulate further alterations during passages and remained stable for at least 3 weeks. We could therefore conclude that these alterations might fail to be seen in the heterogeneous tumor tissues because present in a very small number of cells (< 20%), thus resulting undetectable for CN analysis algorithms [11, 24].
Actually, the true picture of genomic alterations occurring in a tumor can be obtained only performing a genomic analysis directly on tumor cells isolated, for example, by laser capture microdissection, which allows a > 90% of purity  and circumvents the problem of DNA alteration "dilution" due to tissue heterogeneity. However, such a useful technical approach has the not negligible inconvenience of providing cellular material not exploitable for eventual subsequent functional studies.
By performing the genome-wide copy number profiling of a collection of ccRCC primary cultures and corresponding tumor tissues, we demonstrated that these well-characterized primary cultures maintained the genomic alterations of parental tumors. Moreover, their DNA profile remained stable for at least 3 weeks, till to third confluence. Importantly, RCC primary cultures provided greater cell homogeneity and enrichment in tumor component than parental tissues, as proved also by phenotypic characterization, thus enabling a better discrimination of DNA alterations. In this context, SNP array technology demonstrated to be a powerful tool able to confirm the origin of cultured cells and to evaluate sample homogeneity and normal cell contamination. The observation that ccRCC primary cultures retain not only the phenotypic features and the proteomic profile of original tumor tissues but also their genomic profile proves that these short-term cultures are a reliable in vitro model that well represents ccRCC genetics and biology and that prospectively could be used for functional approaches.
A thank to Dr. Paola Brambilla (Institute of Experimental Neurology, Scientific Institute of San Raffaele, Milan), Dr. Paolo Mocarelli (Desio Hospital, University of Milano-Bicocca), Dr. Silvano Bosari (Dept. Medicine, Surgery and Dentistry, Ospedale Maggiore Policlinico, University of Milan), Dr. Valentina Usuelli (Dept. Specialistic Surgical Sciences, Urology Unit, Ospedale Maggiore Policlinico, University of Milan). A special thank to Danila Coradini for scientific editing of the manuscript. This work was supported by grants from the Italian Ministry of University and Research: FIRB 2003 (n. RBLA03ER38_004), PRIN 2006 (n. 69373), FIRB 2007 (Rete nazionale per lo studio del proteoma umano, n. RBRN07BMCT_011).
- Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol. 1997, 183 (2): 131-133. 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
- Hoglund M, Gisselsson D, Soller M, Hansen GB, Elfving P, Mitelman F: Dissecting karyotypic patterns in renal cell carcinoma: an analysis of the accumulated cytogenetic data. Cancer Genet Cytogenet. 2004, 153 (1): 1-9. 10.1016/j.cancergencyto.2003.12.019.View ArticlePubMedGoogle Scholar
- Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ: Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009, 27 (5): 746-753. 10.1200/JCO.2007.15.8345.View ArticlePubMedGoogle Scholar
- Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A, Ringert RH, Jakse G, Fuzesi L: Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res. 2001, 61 (21): 7731-7738.PubMedGoogle Scholar
- Perego RA, Corizzato M, Brambilla P, Ferrero S, Bianchi C, Fasoli E, Signorini S, Torsello B, Invernizzi L, Bombelli S, Angeloni V, Pitto M, Battaglia C, Proserpio V, Magni F, Galasso G, Mocarelli P: Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur J Cancer. 2008, 44 (7): 1039-1047. 10.1016/j.ejca.2008.03.008.View ArticlePubMedGoogle Scholar
- Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S: Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009, 69 (11): 4674-4681. 10.1158/0008-5472.CAN-09-0146.View ArticlePubMedPubMed CentralGoogle Scholar
- Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE: Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res. 2009, 15 (24): 7582-7592. 10.1158/1078-0432.CCR-09-2131.View ArticlePubMedPubMed CentralGoogle Scholar
- Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008, 14 (6): 435-446. 10.1016/j.ccr.2008.10.016.View ArticlePubMedPubMed CentralGoogle Scholar
- Dutt A, Beroukhim R: Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol. 2007, 19 (1): 43-49. 10.1097/CCO.0b013e328011a8c1.View ArticlePubMedGoogle Scholar
- Bacolod MD, Schemmann GS, Giardina SF, Paty P, Notterman DA, Barany F: Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. Cancer Res. 2009, 69 (3): 723-727. 10.1158/0008-5472.CAN-08-3543.View ArticlePubMedPubMed CentralGoogle Scholar
- Goransson H, Edlund K, Rydaker M, Rasmussen M, Winquist J, Ekman S, Bergqvist M, Thomas A, Lambe M, Rosenquist R, Holmberg L, Micke P, Botling J, Isaksson A: Quantification of normal cell fraction and copy number neutral LOH in clinical lung cancer samples using SNP array data. PLoS One. 2009, 4 (6): e6057-10.1371/journal.pone.0006057.View ArticlePubMedPubMed CentralGoogle Scholar
- Balmain A, Gray J, Ponder B: The genetics and genomics of cancer. Nat Genet. 2003, 33 (Suppl): 238-244.View ArticlePubMedGoogle Scholar
- Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, Ferrero S, Bosari S, Signorini S, Rocco F, Perego R, Proserpio V, Raimondo F, Mocarelli P, Battaglia C: Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer. 2008, 7: 6-10.1186/1476-4598-7-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, Yu Y, Xu D, Xiao J, Ma L, Wang G, Cao T, Cao G: Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer. 2008, 123 (5): 1080-1088. 10.1002/ijc.23637.View ArticlePubMedGoogle Scholar
- Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, Harnden P, Eardley I, Selby PJ, Banks RE: Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics. 2006, 6 (9): 2853-2864. 10.1002/pmic.200500549.View ArticlePubMedGoogle Scholar
- Hagenkord JM, Monzon FA, Kash SF, Lilleberg S, Xie Q, Kant JA: Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J Mol Diagn. 2010, 12 (2): 184-196. 10.2353/jmoldx.2010.090118.View ArticlePubMedPubMed CentralGoogle Scholar
- Heinzman JM, Brower SL, Bush JE, Silverman JF: Ex vivo enrichment of malignant carcinoma cells in primary culture. Pathology. 2007, 39 (5): 491-494. 10.1080/00313020701569949.View ArticlePubMedGoogle Scholar
- Perego RA, Bianchi C, Corizzato M, Eroini B, Torsello B, Valsecchi C, Di Fonzo A, Cordani N, Favini P, Ferrero S, Pitto M, Sarto C, Magni F, Rocco F, Mocarelli P: Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. J Proteome Res. 2005, 4 (5): 1503-1510. 10.1021/pr050002o.View ArticlePubMedGoogle Scholar
- Bianchi C, Bombelli S, Raimondo F, Torsello B, Angeloni V, Ferrero S, Di Stefano V, Chinello C, Cifola I, Invernizzi L, Brambilla P, Magni F, Pitto M, Zanetti G, Mocarelli P, Perego RA: Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Am J Pathol. 2010, 176 (4): 1660-1670. 10.2353/ajpath.2010.090402.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008, 68 (3): 664-673. 10.1158/0008-5472.CAN-07-2615.View ArticlePubMedGoogle Scholar
- Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE: Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009, 69 (10): 4143-4149. 10.1158/0008-5472.CAN-08-3112.View ArticlePubMedPubMed CentralGoogle Scholar
- De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B, Leenstra S: The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene. 2008, 27 (14): 2091-2096. 10.1038/sj.onc.1210850.View ArticlePubMedGoogle Scholar
- Sanjmyatav J, Schubert J, Junker K: Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis. Oncol Rep. 2005, 14 (5): 1183-1187.PubMedGoogle Scholar
- Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, Koeffler HP, Ogawa S: Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet. 2007, 81 (1): 114-126. 10.1086/518809.View ArticlePubMedPubMed CentralGoogle Scholar
- Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS: Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001, 158 (5): 1639-1651. 10.1016/S0002-9440(10)64120-X.View ArticlePubMedPubMed CentralGoogle Scholar
- Li G, Cuilleron M, Cottier M, Gentil-Perret A, Lambert C, Genin C, Tostain J: The use of MN/CA9 gene expression in identifying malignant solid renal tumors. Eur Urol. 2006, 49 (2): 401-405. 10.1016/j.eururo.2005.10.025.View ArticlePubMedGoogle Scholar
- Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ: Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008, 123 (2): 395-400. 10.1002/ijc.23496.View ArticlePubMedPubMed CentralGoogle Scholar
- Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, Mosnier JF, Genin C, Tostain J: The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res. 2001, 7 (1): 89-92.PubMedGoogle Scholar
- Signoretti S, Regan M, Atkins M: Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008, 101 (Suppl 4): 31-35.View ArticlePubMedGoogle Scholar
- Kovacs G, Szucs S, De Riese W, Baumgartel H: Specific chromosome aberration in human renal cell carcinoma. Int J Cancer. 1987, 40 (2): 171-178. 10.1002/ijc.2910400208.View ArticlePubMedGoogle Scholar
- Shi T, Dong F, Liou LS, Duan ZH, Novick AC, DiDonato JA: Differential protein profiling in renal-cell carcinoma. Mol Carcinog. 2004, 40 (1): 47-61. 10.1002/mc.20015.View ArticlePubMedGoogle Scholar
- Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010, 107 (43): 18545-18550. 10.1073/pnas.1010978107.View ArticlePubMedPubMed CentralGoogle Scholar
- Lo KC, Bailey D, Burkhardt T, Gardina P, Turpaz Y, Cowell JK: Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer. 2008, 47 (3): 221-237. 10.1002/gcc.20524.View ArticlePubMedGoogle Scholar
- Ochs RL, Fensterer J, Ohori NP, Wells A, Gabrin M, George LD, Kornblith P: Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. In Vitro Cell Dev Biol Anim. 2003, 39 (1-2): 63-70.View ArticlePubMedGoogle Scholar
- Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, Nakamura Y: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 2004, 25 (4): 797-819.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/244/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.